http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#Head http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#assertion http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#provenance http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#pubInfo http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#assertion http://purl.obolibrary.org/obo/MONDO_0005090 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0005090 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/DRUGBANK:DB01267 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association http://www.w3.org/2000/01/rdf-schema#label Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12) http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#context http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/31096228 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#context http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#context http://www.w3.org/2000/01/rdf-schema#label Children and adolescents (6-17 years) https://identifiers.org/DRUGBANK:DB01267 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#provenance http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#assertion http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T15:53:57.790445 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#pubInfo http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#sig http://purl.org/nanopub/x/hasSignature bFZGs0c7LGBIG9dBqo1HIEG03MRkRrue798pF+lybU9f9VuCouDPFCGpMLcCtOY415i4CEcZzffP3RU1MxCNdk1lWl2aN7doGS+Tn/DhmzWDesT6wHJ+2ra/sFejnD0StU7BwOV3FzcbUiPYTTqDcpua6sCJvHIb+RHW+oq3fCg= http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T15:53:57.790445 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAMDl6w7lXZQYDUuT98vjAY5zXIoMStqKs-H3bdtrZKLU https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY